{"ts": 1769396841.835807, "content": "Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403 TitlePharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403Cat 0 0 18 Dec 2025 Views 861 Press Release PharmAbcine\u2019s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors Title PharmAbcine\u2019s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in P 0 0 21 Aug 2025 Views 2762 News Article PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025_THE BIO TitlePharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025 CategoryNews 0 0 9 Jun 2025 Views 3434 Press Release PharmAbcine\u2019s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors TitlePharmAbcine\u2019s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced 0 0 19 May 2025 Views 3758 Media Center Subscribe to our website to get latest updates (email@exmaple.com) Subscribe Confirm No Category Show all Press Release News Article PR Video CEO Story Title Author Time uploaded Views Likes 69 Press Release Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403 (\uc8fc)\ud30c\uba65\uc2e0 18 Dec 2025 Views 861 0 68 Press Release Press Release PharmAbcine\u2019s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors (\uc8fc)\ud30c\uba65\uc2e0 21 Aug 2025 Views 2762 0 67 Press Release Press Release PharmAbcine\u2019s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors (\uc8fc)\ud30c\uba65\uc2e0 19 May 2025 Views 3758 0 66 Press Release Press Release PharmAbcine at JP Morgan Healthcare Conference 2025 (\uc8fc)\ud30c\uba65\uc2e0 10 Jan 2025 Views 4879 0 65 Press Release Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration (\uc8fc)\ud30c\uba65\uc2e0 9 Jan 2025 Views 4199 0 64 Press Release Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration PharmAbcine 16 Oct 2024 Views 4467 0 63 Press Release Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors PharmAbcine 9 Jul 2024 Views 5250 0 62 Press Release Press Release PharmAbcine\u2019s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg PharmAbcine 2 Jul 2024 Views 4828 0 61 Press Release Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024 PharmAbcine 23 May 2024 Views 5091 0 60 Press Release Press Release Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 PharmAbcine 23 Apr 2024 Views 4942 0 Search New post About Us Executive Committee Board of Directors Scientific Advisory Board History Core Technology Fully Human Antibody Library Antibody Development Antibody Engineering Pipeline Olinvacimab PMC-309 PMC-402 PMC-403 For Investors For Media Careers Recruiting Procedure Careers Guide Job Openings Contact Location Inquiry Partnership Request LinkedIn I Facebook I YouTube 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea HQ +82-42-863-2017 R&D Center +82-42-861-2017 FAX +82-42-863-2080 COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.", "type": "text"}